Hepatology

Article	Citations
Letter to the Editor: Association between hepatitis delta virus with liver morbidity and mortality—A systematic literature review and meta-analysis	1286
Real-world evidence for factors associated with maintenance treatment practices among US adults with autoimmune hepatitis	1125
Selective genetic inactivation of Caspase 8 in hepatocytes ameliorates progression of MASH following Jnk deficiency	1068
Assessment of liver injury potential of investigational medicines in drug development	639
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	458
Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition	400
Cholestatic liver diseases of genetic etiology: Advances and controversies	319
Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial	289
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study	269
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	244
Steatotic Hepatocytes Release Mature VLDL Through Methionine and Tyrosine Metabolism in a Keap1‐Nrf2–Dependent Manner	209
Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis	200
The Clinical Significance of Hepatic CD69+CD103+CD8+ Resident‐Memory T Cells in Autoimmune Hepatitis	189
	182
	173
Retracted: Posttranslational regulation of polycystin‐2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage	163
Mitochondrial genome diversity drives heterogeneity in hepatocellular carcinoma	161
Letter to the Editor: Association of hepatitis D virus infection with liver-related outcomes	157
New ubiquitomic subtypes in hepatocellular carcinoma: Insights for future therapeutic approaches	151
Beyond monotherapy: Combining radiotherapy with sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus	150
Second Line, Still Fine	147
Reply: The causal analysis of missing confounding factors for the association between HDV and specific liver events	143
The impact of LRP4 mutations on HCC recurrence and immunotherapy response	141
Reply: Accurate predictor for liver disease progression in patients with DC/TBD	141
Telomere dysfunction in chronic liver disease: The link from aging	141

Letter to the Editor: Molecular classification based on multi-omics facilitates prognostic stratification and personalized treatment in hepatocellular carcinoma	139
Retracted	136
Identification of optimal portal pressure decrease to control ascites while minimizing HE after TIPS: A multicenter study	132
Letter to the Editor: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	132
Prevalence and predictors of cirrhosis and portal hypertension in the United States	129
ASK1/p38 axis inhibition blocks the release of mitochondrial “danger signals” from hepatocytes and suppresses progression to cirrhosis and liver cancer	126
NK-cell–elicited gasdermin-D–dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitate HBV-related acute-on-chronic liver failure	124
Single-cell immune profiling of mouse liver aging reveals Cxcl2 + macrophages recruit neutrophils to aggravate liver injury	123
Sphingosine‐1‐phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy	121
	118
Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression	118
Harnessing ZIKV NS2A RNA for alleviating acute hepatitis and cytokine release storm by targeting translation machinery	116
Beyond circadian rhythms: emerging roles of ultradian rhythms in control of liver functions	114
Maternal Early‐Pregnancy Glucose Concentrations and Liver Fat Among School‐Age Children	113
Methyltransferase 1 is required for nonhomologous end‐joining repair and renders hepatocellular carcinoma resistant to radiotherapy	111
Human-induced pluripotent stem cell–based hepatic modeling of lipid metabolism–associated TM6SF2-E167K variant	110
Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma	110
Obeticholic acid as second-line therapy for primary biliary cholangitis: Does target trial emulation solve the issue?	110
Letter to the Editor: Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline	108
Letter to the Editor: Clonally expanded CD8+ T cells in MASH—Invited guests overstaying their welcome	107
Letter to the Editor: The WHO HDV RNA international standard does not reflect variability of real-world samples	105
Utility of methylated DNA markers for the diagnosis of malignant biliary strictures	103
Reply: Clonally expanded CD8+ T cells in MASH—Invited guests overstaying their welcome	102
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	100
Aramchol improves hepatic fibrosis in metabolic dysfunction–associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology	98
Management of patients with advanced HCC receiving atezolizumab/bevacizumab: Take care of cirrhosis!	98
Letter to the Editor: A positive step toward cost-effective and accessible HCC detection awaits further validation	97
Reply: Fiber and whole grain intakes in relation to liver cancer risk: An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	96
Hepatic encephalopathy - We are no longer those who believe that reality is what we perceive	96
Reply: Liver transplantation for primary and secondary liver tumors—Patient-level meta-analyses compared to UNOS conventional indications	94
Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in HSCs	93
A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression	92
Combined High‐Dose Continuous Renal Replacement Therapy and Plasma Exchange in the Management of Severe Multiorgan System Dysfunction Associated With Acute Liver Failure	92
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease	91
DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes	90
A Beautiful Day in the Neighborhood: Application of Single‐Cell Transcriptomics to Unravel Liver Cell Heterogeneity in Diseased Human Livers	89
MetALD: Does it require a different therapeutic option?	88
Cracking HCC: Targeting diacylglycerol kinase eta to tackle therapy resistance and cancer stemness	88
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	86
Liver transplantation for alcohol-associated liver disease	86
A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases	85
Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor signaling	84
Uncovering epigenetic heterogeneity in HCC	83
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	82
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	82
Pharmaceutical SH2 domain–containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity	81
Late-Breaking Abstracts	81
Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant	80
Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC?	80
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	80

PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	79
Back to phosphodiesterase inhibitors for liver disease: are we ready for clinical trials?	78
Mdka produced by the activated HSCs drives bipotential progenitor cell redifferentiation during zebrafish biliary-mediated liver regeneration	76
Letter to the Editor: Portal vein thrombosis in cirrhosis: The issue of treatment	76
Rise above the stress—Endoplasmic reticulum stress and autophagy enhance the release of hepatitis B virus subparticles	75
Outcomes of severe alcohol‐associated hepatitis with or without early liver transplantation	74
Reply	73
Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity	73
Letter to the editor: Autoimmune hepatitis after COVID‐19 vaccination: A rare adverse effect?	73
Letter to the Editor: Rethinking public health measures to reduce liver injury from therapeutic acetaminophen ingestion	72
Letter to the editor: Short‐term data on machine perfusion should be extrapolated with caution	72
Masthead	72
Reply	71
Hepatology Highlights	71
Table of contents	70
Instructions to Authors	70
Reply	69
Letter to the editor: Complications following SARS‐CoV‐2 infection in patients with chronic liver disease	69
Reply	69
Bariatric surgery meets TREM2+ macrophages to alleviate MASH independent of weight loss	68
Reply: Liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus	68
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	68
Single‐cell biology uncovers apoptotic cell death and its spatial organization as a potential modifier of tumor diversity in HCC	68
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	67
Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis	67
Reply	66
Prediction of biochemical nonresolution in patients with chronic drug‐induced liver injury: A large multicenter study	65
Pediatric NASH therapies: A speedbump on the road to success	64
Letter to the editor: Is transjugular intrahepatic portosystemic shunt the best treatment for adults without cirrhosis with extrahepatic portal vein obstruction and portal hypertension?	64
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	64
Cover Image	64
Cover Image	63
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	63
Digitizing DILI: Who can? RUCAM? RECAM?	62
Will inhibition of cellular crosstalk resolve liver fibrosis?	62
Reply	62
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	62
Letter to the editor: Using angiotensin‐converting enzyme inhibitors to prevent liver‐related events in NAFLD—Revisiting the renin–angiotensin–aldosterone system pathways	62
Reply	62
Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron‐induced hepatotoxicity	61
Erratum: HCC EV ECG score: An extracellular vesicle‐based protein assay for detection of early‐stage hepatocellular carcinoma	61
Information for Readers	61
Improving the fitness of the NASH clinical trial: Standardizing the standard‐of‐care intervention	61
Reply	61
Letter to the editor: Prediction of biochemical nonresolution in patients with chronic drug‐induced liver injury: A large multicenter study	61
Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis	60
Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC	60
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	60
Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?	59
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	59
Reply	59
Paul David Berk, editor extraordinaire and bilirubinologist	59
Letter to the Editor: Is HBV genotype strongly associated with HCC risk in patients with chronic hepatitis B?	59
Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients	58
Erratum: Interleukin-18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis	58
SIRT and chemotherapy in unresectable iCCA: Ready to take off	57
Letter to the editor: discussing the place of TIPS in noncirrhotic patients with chronic extrahepatic portal vein occlusion (EHPVO)	57
Hepatology Highlights	57
Reply	57
Reply: Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management	57
Letter to the editor: Low sensitivity of RT‐Alu‐PCR in detection of HBV integrated chimeric transcripts	57
Seeking Editor for Hepatology Communications	56
Letter to the editor: Could COVID‐19 vaccination reduce postinfection mortality in most patients with cirrhosis?	56
Masthead	56
Aseptic Liver Abscesses as an Exceptional Finding in Cogan’s Syndrome	55
Letter to the Editor: How F to S turned the premature to be mature?	55
Hepatitis B surface antigen seroclearance is uncommon but durable in the long run	55
Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system	55
Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma	55
Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time	55
Letter to the Editor: Mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation—Are there other challenges?	54
Gene Signatures Reduce the Stress of Preclinical Drug Hepatotoxicity Screening	54
Letter to the Editor: Updated guidance on NAFLD screening	54
Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans	54
Author Index	54
Thematic reviews: The future of hepatology	54
A developmentally prometastatic niche to hepatoblastoma in neonatal liver mediated by the Cxcl1/Cxcr2 axis	53
Letter to the Editor: Benefits of stopping therapy in patients with cirrhotic hepatitis B, true effect or residual confounding?	53
Unfolding the mechanism of hepatocyte injury of HBV precore and core promoter variants	53
Treatment of autoimmune hepatitis: Budesonide does not solve our problems	53

Hepatocytes of mice and men: Different regenerative signals?	53
Letter to the Editor: The Potential Mechanism by the Protection Effects of Exercise Training on Ischemia/Reperfusion–Induced Injury and Metastasis	52
Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma	52
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	51
Erratum: Blockade of T‐cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV‐related HCC in mice	51
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	51
Therapeutic Potential of G Protein‐Coupled Receptors Against Nonalcoholic Steatohepatitis	50
Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation‐driven hepatocarcinogenesis	50
Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: An analysis of the All-Payer Claims Database	50
Letter to the editor: Combination treatment with IL‐1 antagonist, pentoxifylline and zinc for severe alcoholic hepatitis: Are we there yet?	50
Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol‐Associated Liver Disease	49
Masthead	49
Preventing 2 viral infections with 1 tablet	49
Instructions to Authors	49
REPLY:	49
Instructions to Authors	48
Letter to the Editor	48
Should PNPLA3 polymorphism be performed in clinical practice in patients with NAFLD to predict the risk of disease progression?	48
Correction	48
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	47
Letter to the Editor: Variability in serum creatinine is associated with waitlist and post–liver transplant mortality in patients with cirrhosis	47
Using global burden of hepatocellular cancer and liver cirrhosis as a driver to tackle preventable mortality and morbidity nationally and regionally	47
Instructions to Authors	47
August Hepatology Highlights	47
Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function	47
Letter to the Editor: Why Serum Hepatitis B Virus (HBV) DNA Has Higher Frequency of rtM204I/V Mutation Than Serum HBV RNA in the Same Individual?	47
Instructions to Authors	47
Obituary for Roberto J. Groszmann—The Father of Portal Hypertension	46
REPLY:	46
Risk of cardiovascular disease and loss in life expectancy in NAFLD	46
ASO silencing of a glycosyltransferase, Poglut1, improves the liver phenotypes in mouse models of Alagille syndrome	46
Quantifying days at home in patients with cirrhosis: A national cohort study	46
Navigating liver disease complexity: Innovations in in vitro modeling and precision medicine	46
Matrisomic characterization of HCC to inform individualized patient management	46
Farnesoid X Receptor Activation Impairs Liver Progenitor Cell–Mediated Liver Regeneration via the PTEN‐PI3K‐AKT‐mTOR Axis in Zebrafish	46
Letter to the Editor: Examining HBV‐RNA Kinetics During NA Treatment—Are NAs Multifunctional Antiviral Agents?	45
Successful Management With Dual Therapy of Lenvatinib and Macitentan for HCC With Portopulmonary Hypertension	45
Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut‐Off Approach	45
VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure	44
Population-based proteomics: Platforms to advance diagnosis and treatment of metabolic liver diseases	44
Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial	44
REPLY:	44
The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study	44
Predicting liver-related events in NAFLD: A predictive model	44
Letter to the Editor: Progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease	44
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	43
Letter to the Editor: The Differences Between the Reverse Transcriptional Efficiency of HBV Pregenomic RNA and Transcriptional Efficiency of HBV Covalently Closed Circular DNA	43
Letter to the Editor: H19 Promotes HCC Bone Metastasis by Reducing Osteoprotegerin Expression in a PPP1CA/p38MAPK‐Dependent Manner and Sponging miR‐200b‐3p	43
Two important players in poor-prognosis hepatocellular carcinoma: Extrachromosomal circular DNA (eccDNA) and its passenger, the oncogenic miR-17~92 locus	43
Letter to the Editor: Response to Terlipressin Plus Albumin in Hepatorenal Syndrome—Need a Closer Look!	42
Letter to the Editor: Health warning for humble writers, distracted reviewers, and naive readers	42
Letter to the Editor: Comment on “The Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases”	42
Erratum: Modulation of the tryptophan hydroxylase 1/monoamine oxidase‐A/5‐hydroxytryptamine/5‐hydroxytryptamine receptor 2A/2B/2C axis regulates biliary proliferation and liver fibrosis during cholest	42
Letter to the Editor: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the recurrence of PSC?	42
Reply	42
Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria	42
Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease	41
Hypoxia‐Inducible Factor 1 Alpha–Mediated RelB/APOBEC3B Down‐regulation Allows Hepatitis B Virus Persistence	41
Reply: Consensus subtypes of HCC associated with clinical outcomes and genomic phenotypes	41
Abstracts	41
Reply: Questioning the existence of Aif1 +, Csf1r + mesenchymal stem cells	41
Letter to the Editor: Immune‐Mobilizing Monoclonal T‐Cell Receptors: A Novel Addition in the HBV Armamentarium	41
Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression	41
A Possible Association Between a Nucleotide‐Binding Domain LRR‐Containing Protein Family PYD‐Containing Protein 1 Mutation and an Autoinflammatory Disease Involving Liver Cirrhosis	41
Letter to the Editor: Concerns regarding the use of fatty liver index in studies of lean NAFLD	41
Instructions to Authors	40
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	40
Letter to the Editor: Portable hypothermic oxygenated machine perfusion for organ preservation in liver transplantation (PILOT)	40
Modifiable risk factors for fatty liver disease: Time to act	40
Letter to the Editor: Nonalcoholic Fatty Liver Disease—One Size May Not Fit All	40
Erratum: Abstracts	39
Introducing the Editorial Fellow and the Fellows’ Corner	39
Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis	39
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	39
Letter to the Editor: Hepatocellular Carcinoma Surveillance in Cirrhosis Patients: Is the Real‐World Situation Even Worse Than Reported?	39
Reply	39
Letter to the Editor: Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis	38
Hepatology highlights	38
IgG 4 Autoimmune Hepatitis Presenting as Idiopathic Hypereosinophilia Syndrome	38
Letter to the Editor: Liver Cell Models for Premature Termination Codon Readthrough Analyses	38
Sumoylation of methionine adenosyltransferase alpha 1 promotes mitochondrial dysfunction in alcohol-associated liver disease	38
Chyme Reinfusion Restores the Regulatory Bile Salt–FGF19 Axis in Patients With Intestinal Failure	38
Letter to the editor: l‐ornithine l‐aspartate in acute treatment of severe hepatic encephalopathy: A double‐blind randomized controlled trial	38
Access to technology to support telehealth in areas without specialty care for liver disease	37
Liver-restricted deletion of the biliary atresia candidate gene Pkd1l1 causes bile duct dysmorphogenesis and ciliopathy	37
Can We Rely on Changes in HVPG in Patients with Cirrhosis?	37
April 2024 Hepatology Highlights	37
Transcriptomic Analysis Reveals the MicroRNAs Responsible for Liver Regeneration Associated With Mortality in Alcohol‐Associated Hepatitis	37
Reply: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome—First report of the IAIHG retrospective registry	37
Letter to the editor: Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD	37
Letter to the Editor: High Mobility Group Box Protein 1 Release Is an Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia	37
Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population	37
It could happen in your backyard	36
Letter to the editor: Postvaccination COVID‐19‐related mortality in patients with cirrhosis: Who is the culprit?	36
Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction	36